Allison T. Rhoads, PharmD

Studies suggest novel immunotherapy may have efficacy as monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.

Asundexian was granted FDA Fast Track Designation based on a phase 2 study evaluating its safety and efficacy combined with antiplatelet therapy in patients following an acute, non-cardioembolic ischemic stroke.